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Glossary of terms used in this thesis  
 
Accuracy -  the nearness of an experimental measurement to the true 
value. The accuracy of a method is linked to the use of 
certified reference materials.  
 
Analyte -    the chemical species to be identified or quantified. 
 
Baseline -  similar to the background, but usually a reference to 
plotted data in a spectrum or chromatogram. The average 
value of blank measurements or the average minimum 
where there are no peaks.  
 
Bioanalysis - is the sub-discipline of analytical chemistry covering the 
quantitative measurement of xenobiotics (drugs and their 
metabolites, and biological molecules in unnatural 
locations or concentrations) and biotics 
(macromolecules, proteins, DNA, large molecule drugs, 
metabolites) in biological systems. 
 
Blank -  a standard containing no analyte, for example a 
concentration of 0.0.  
 
Calibration -  the process of measuring a known quantity to determine 
the relationship between the measurement signal and the 
analyte amount or concentration.  
 
Calibration curve Ȃ  a plot of signal versus analyte amount or concentration. 
Used to calibrate a measurement over an extended range. 
Good practice is to measure five to ten standards that are 
equally spaced through the measurement range. 
 
Cannabinoid- a cannabinoid is one of a class of diverse chemical 
compounds that act on cannabinoid receptors in cells 
that alter neurotransmitter release in the brain.  
 
Carry over - residual analyte in a sample preparation or measurement 
step that causes the measurement to be higher that the 
true value. 
 
Certified Reference Material Ȃ a material that is verified to contain a known  
   amount of analyte. 
 







Chromatography - a technique for analysing or separating mixtures of gases, 
liquids or dissolved substances, into their individual 
components. Separation is achieved by passing the 
components in solution or suspension through a medium 
in which the components move at different rates. 
 
Contaminant - a substance, which can include the analyte itself, which is 
introduced unintentionally into a sample during 
collection, processing or measurement. 
 
Drift -   the gradual change in blank measurements over time. 
 
Duplicate Sample Ȃ  a sample that is split in to two portions to monitor 
method variability. 
 
Error, Random Ȃ  the spread in replicate measurements due to random 
fluctuations. Will be both higher and lower than true 
value. 
 
Error, Systematic Ȃ  a consistent difference either higher or lower between an 
experimental measurement and the true value. Can differ 
from sample to sample depending on variability in sample 
matrix effects.  
 
Excipient -  an inactive substance that serves as a vehicle or medium 
for a drug or other active substance. 
 
Internal Standard Ȃ  a known standard added directly to the sample or blank. 
The internal standard is then measured simultaneously 
with the analyte.  
 
Limit of Detection (LOD) Ȃ  the minimum measured concentration at which 
an analyte may be reported as being detected in a sample. 
There are several accepted methods to determine an 
LOD. A simple method is to calculate the concentration 
that corresponds to a signal level that equals the baseline 
plus 3 times the noise.   
  
Limit of Quantitation (LOQ) Ȃ the minimum measured concentration at 
which an analyte concentration may be reported. A 
simple method is to calculate the concentration that 
corresponds to a signal level that equals the baseline plus 






Mass-to-charge ratio (M/Z) Ȃ is the ratio of the mass number (m) of a given 
particle to the number (z) of electrostatic charge units (e) 
carried by the particle. Thus, m/z is mass divided by 
charge number.  
 
Matrix Effect Ȃ  the effect on a measurement resulting from components 
in the sample. Can vary sample to sample and impact the 
result higher or lower. Specific species that are that are 
identified as causing a systematic error are called 
interferences.  
 
Memory effect Ȃ  an apparent signal in an instrumental measurement that 
occurs due to contamination or carry over from a 
previous test sample.  
 
Noise -  random fluctuations in the signal. Usually quantified 
using the standard deviation of multiple measurements of 
the blank. 
 
Precision -  the repeatability in making replicate measurements. 
Imprecision, or the lack of precision, is probably a better 
term to describe the repeatability of measurements, but 
precision is the more common term. Qualitative 
measures include standard deviation, standard error and 
confidence limits.  
 
Repeatability Ȃ  comparison of replicate measurements made on the same 
sample and performed under identical conditions.  
 
Replicate Measurements Ȃ multiple measurements of the same sample. 
Replicate measurements can be made by dividing the 
sample in to several test portions and testing each portion 
separately. Doing such a test can provide a measure of 
precision of the method and can identify outliers due to 
gross errors (blunders) such as omitting a step in a 
protocol, instrument glitches or incorrectly recorded 
values.  
 
Reproducibility Ȃ  comparison of replicate measurements made on the same 
test sample made by different analysts. The calculation of 
precision is the same for repeatability and reproducibility, 
the difference is the source of the measurement results. 
 
Resolution -  the minimum difference between separated peaks in a 
chromatogram or spectrum.  
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Ruggedness -  the degree to which variable experimental conditions 
such as temperature, pH, ionic strength, will affect the 
accuracy and precision of a measured result.  
 
Selectivity -  the ability of a method or instrument to measure an 
analyte in the presence of other constituents of a sample. 
 
Sensitivity - the slope of the calibration function, i.e., the change in 
the detector signal versus the change in the amount of 
analyte.  
 
Signal-to-Noise ratio (S/N) Ȃ the ratio of the signal to the baseline noise. 
 
Smoothing - averaging adjacent points in a spectrum to reduce the 
apparent noise. 
 
Spike -  an internal standard or standard addition added to a 
sample or blank. 
 
Stability - retention of analyte over time or during sample 
preparation and analysis steps.  
 
Standard Operating Procedure (SOP) Ȃ a document containing the 
instructions for a specific analytical procedure or 
instrument. 
 
Therapeutic Drug Monitoring (TDM) Ȃ is a branch of clinical chemistry and 
clinical pharmacology that specialises in the 
measurement of medication concentrations in blood. Its 
main focus is on drugs with a narrow therapeutic 
window. 
 
Thermally Unstable Ȃ if a substance is thermally unstable it means it breaks 
down at high temperatures. Therefore, it cannot 
withstand high temperatures. 
 
Volatile -  the word volatile refers to a substance that vaporizes 
readily. Volatility is a measure of how readily a substance 
vaporizes or transitions from a liquid phase to a gas 
phase.  






Cremophor EL (CrEL) is an excipient widely used in the pharmaceutical 
industry, which is derived from the castor oil plant (Ricinus communis). CrEL 
is produced by reacting castor oil with ethylene oxide at a molar ratio of 1:35. 
Patients who have advanced or multiple cancer sites are commonly treated 
using chemotherapeutic agents. Such mixtures are comprised of a drug 
compound and an excipient carrier which enable the agent to reach its 
intended site more efficiently. In high concentration, there is evidence to 
suggest that CrEL may be toxic to those undergoing chemotherapy. Therefore, 
CrEL should be monitored in order to reduce the incidence of adverse 
reactions. The measurement of CrEL in human plasma has been previously 
reported using a number of different analytical techniques ranging from the 
simple colorimetric dye assays to High Performance Liquid Chromatography 
with Ultraviolet detection. Throughout many of these techniques CrEL proved 
particularly difficult to measure using labour intensive sample preparation, 
which lacked sensitivity, reproducibility and linearity.  
 
The purpose of this study was to develop and validate a Liquid 
Chromatography tandem Mass Spectrometry (LC-MS/MS) method for the 
determination of CrEL in human plasma, which could be applied to a Phase 1 
Pharmacokinetically (PK) guided, dose escalation study for patients with 
advanced solid tumours. CrEL was extracted from plasma by liquid-liquid 
extraction using a mixture of Chloroform: Methanol (2:1 v/v) and butylated 
hydroxy toluene (BHT). Sodium hydroxide was added to the samples to 
release Ricinoleic acid. The resulting extracts were then analysed using the 
Waters Ultra Performance Liquid Chromatography and the Quattro Premier 
Tandem Mass Spectrometry. Separation of CrEL in the LC was achieved using 
an HSS T3 column 1.8 µm (hybrid particle) 2.1 mm x 100 mm and ionised using 
electrospray in negative mode. Multiple reaction monitoring (MRM) was 
carried out with a transition of m/z 279.3 ĺ 182.9. The assay performed well 
with no evidence of ion suppression and enhancement or carry over.   
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The lower limit of quantification was 0.07 µl/mL and the calibration curve in 
plasma was linear over the range 0.07 to 10.0µg/L with an excellent correlation 
coefficient (r²) >0.99. The assay precision was also excellent, intra assay and 
day to day co-efficient of variation (CV) reporting 17% for the low level and 
10% on the high level. 
 
This assay is now in routine use in a Hampshire laboratory where a PK study 
of patients with advanced solid tumours is being investigated. Patients are 
dosed with Dexanabinol a synthetically altered cannabinoid drug in 
combination with the excipient CrEL. Plasma samples are then analysed to 
evaluate the pharmacokinetics and assess the safety of the prescribed 










The main objectives of this study were to: 
 
x Develop and validate a fast, selective and sensitive method for the 
quantitative determination of CrEL in human plasma using a 
chromatography platform within the laboratory.  
x To provide a method that is both robust and accurate, whilst still 
enabling the high throughput of clinical trial samples. CrEL levels 
across cohorts must be quickly analysed and assessed, before the next 
dose is prescribed.   
 
1.1.2 Research Aims  
 
During the initial stages of this study many of the previous methods were 
researched in order to understand how CrEL has been analysed and what 
analytical platforms had been used. The principal purpose of this study was to 
develop and validate a fast and accurate method, capable of monitoring CrEL 
concentrations and giving a reliable value. The method would need to 
complement the existing Dexanabinol extraction, which was already in place. 
Dexanabinol is being investigated to establish the maximum safe dose that can 
be prescribed to patients with advanced solid tumours. Another important 
factor was to keep the run times short and the analyte recoveries high. The 
limit of detection (LOD) should be low to satisfy the normal criteria for 
therapeutic drug monitoring (TDM), but the analytical range should be 
sufficient allowing for both high and low levels to be quantified.  
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A selection of papers were researched at the start of the study, but only a 
handful of methods used the technique of Liquid Chromatography Ȃ tandem 
mass spectrometry (LC-MS/MS), many relied upon Gas Chromatography Ȃ 
Mass spectrometry (GC-MS). Both platforms are available within the 
laboratory to use in this study.  
 
The two platforms have many differences in relation to sample extraction and 
the way in which the analyte is carried through the system. GC-MS relies 
heavily upon the analyte being volatile and thermally stable, whereas LC-
MS/MS is useful for analytes that are thermally unstable and non-volatile. 
Having access to the two platforms and understanding the type of compounds 
that works best on each, will be beneficial during the method development 
process. 
 
1.2. Cremophor, Cancer and Chemotherapy 
 
1.2.1. Cremophor  
 
Cremophor (Polyoxyethyleneglycerol triricoleate 35), also commonly known as 
Cremophor EL (CrEL) or more recently Kolliphor EL, is a synthetic solubiliser 
and emulsifying agent currently used as an excipient or carrier for the active 
ingredients of a drug.1  CrEL use is well established in the pharmaceutical 
industry, where it has been used in combination with a wide variety of 
hydrophobic compounds including anaesthetics, sedatives, 
immunosuppressant agents and anticancer drugs.2 CrEL is produced by 
reacting castor oil with ethylene oxide at a molar ratio of 1:35.1 Castor oil is 
derived from the plant Ricinus communis (Figure 1) by pressing the seeds 
(Figure 2)3 The oily substance is mainly composed of triglycerides of which 
87% is Ricinoleic acid the primary component4. It is presently undergoing 





Figure 1: Ricinus communis plant5 and castor oil seeds6. 
 
 
 Cremophor MW7 = 2560.0   Ricinoleic acid MW8 = 298.46 
Figure 2: The chemical structures of CrEL and Ricinoleic acid 
 
Evidence suggests that CrEL may be toxic at high doses. It is therefore 
important to monitor plasma drug levels in order to reduce the incidence of 
these side effects.9 Common side effects include nausea, vomiting, joint pain, 




The side effects that can potentially be life-threatening are immunological 
hypersensitivity reactions such as anaphylaxis, where the body becomes 
hypersensitive to a specific antigen causing an acute response.11 Other factors 
to consider during the administration of cytotoxic drugs and their excipients 
are the suitability of the infusion set used or storage container.  
 
Previous studies have noted that CrEL is known to leach plasticizers such as 
di(2-ethylhexyl)phthalate from polyvinylchloride bags and polyethylene lined 
tubing.10  Such occurrences could lead to additional hypersensitivity reactions  
or an allergic response if the components are released in to the ǯ 




Excipients are typically inactive substances that have no medicinal properties, 
they can act as a medium to bulk, a substance to reduce absorption during 
admission or as a vehicle to aid in drug delivery. During the development of 
pharmaceutical agents many obstacles have to be overcome, one of which is 
ensuring that a compound reaches its intended site of action. Excipients are 
crucial to drug delivery within the body and to facilitate physiological 
absorption of the drug. Additional capabilities served by excipients products 
are; lubricity, flow-ability, solubility, reducing viscosity, disintegration, 
reduced degradation, taste and possibly some antimicrobial function.12, 13   
 
In this study CrEL is combined with Dexanabinol to act as a carrier as seen in 
Table 1, thus preventing absorption into only the intravenous site during drug 
admission. Other excipients are also added to the formulation including 
ethanol, EDTA and Tocopherol, to improve drug solubility and long term 
stability. Dexanabinol as a single compound is extremely lipophilic and 




Carrier excipients are designed to interact with and enhance the properties of 
the active pharmaceutical ingredients (APIs), while not having any chemical 
effect on the action of the agent.  
 
The ingredient qualities are promoted by the carrier excipients and have 
become useful tools for drug formulators. Long term stabilisation of low 
quantity ingredients and bulking up solid formulations is also possible now 
with excipients.14 
 
Active component Treatment dosage vial contains Dexanabinol plus  
Excipients DL-Tocopherol  
Ethylenediaminetetraacetic acid (EDTA)  
Ethanol Absolute  
Cremophor EL  
Table 1: Excipients present in the Dexanabinol formulation that will be 




In the modern world, the known incidence of cancer has risen from 12.7 
million in 2008 to 14.1 million in 2012.15 The current incidence projection rates 
estimate that within two decades that figure could reach 25 million.15 The 
human body of an average sized person is comprised of roughly one thousand 
billion cells. Cells are recognised as the general building blocks of life and 
form our tissues and organs. The term cancer is best described as the 
continual, uncontrolled production of cells that are no benefit to the body.16 
Cancer is commonly recognised as a growth or lump caused by the 
proliferation of cells that spread beyond their normal space if left untreated. A 
common misconception is that cancer is a single disease, when it is more 
accurately classified as a group of disorders with differing symptoms.  
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Additionally, proliferation without swelling can also occur and is typically 
found in cases of leukaemia and lymphoma, where the blood forming cells 
found in bone marrow are affected.17  
 
Cancer cells differ from other normal cells because they can multiply 
indefinitely and have the ability to migrate to other sites in the body resulting 
in metastases.17 Metastasis is the formation of secondary tumours in other 
tissues or organs that differ from the primary origin.18 The affected cells also 
differ from normal other cells because they cease to perform their intended 
function for a particular site in the body. Liver cells for example remove toxic 
chemicals from blood and nerve cells transmit electrical signals.  
 
Specific cell functions help to keep an organism in equilibrium, and cells 
without a function are seen as independent cells, still requiring nutrition and 
support from the host at the expense of other healthy cells which benefit the 
host.17  
 
Cancer can be classified in to two categories benign and malignant (Figure 3). 
Cancers that spread from one site to other body areas are normally classified 
as malignant and recognised as cancerous. Benign growths differ because they 
divide quickly but remain in one place and are commonly non-cancerous. 
Benign cells often remain in a capsule structure and unlike malignant cells do 
not invade other tissues facilitating the possibility of surgical removal.19 
Malignant growths manifest in other tissues by producing chemicals which 
break down healthy tissue. This makes malignant tumours particularly 
difficult to separate surgically because it is almost impossible to differentiate 
between healthy and cancerous tissue. When malignant tissue is bound to 
healthy tissue or organs, complete removal is impossible without serious 
damage to the system or organ. Surgeons faced with this scenario have to 
adopt a different technique called cytoreduction surgery or more commonly 
tumour debulking.20  
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The principle of the surgery procedure focuses upon the removal of the 
tumour and some healthy tissue while still allowing the system to function. 
Some patients who have undergone such procedures have responded better to 
radiotherapy and chemotherapy, have lived longer and had some symptom 
relieved. 20 
 
Figure 3: image showing the major differences between normal cells when 
compared to benign and malignant cells. 
http://stomach.cancertheory.jp/cancer_theory/outline/carcinogenesis/index.ph
p  (Accessed August and September 2017).   
Malignant tumours are generally the most likely to cause harm, but if benign 
growths establish in confined spaces such as the skull they too have potential 
to cause harm by blocking important structures such as blood vessels or 
nerves. Malignant growths commonly have an irregular or ulcerated surface 
and can quickly spread to other sites if the cells enter the lymphatic or 
circulatory systems.16 
 
The cancer type is normally determined by obtaining a biopsy which is viewed 
under a microscope to understand its behaviour.  
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Certain cancers can be identified by checking for chemical markers present in 
the blood. Prostate-Specific Antigen (PSA) for example is a good indicator of 
prostate cancer when high levels are present. Cancers are categorized in to 
further types as seen in Table 2.  
 
Cancer group Description Incidence rate in UK 
Carcinoma 
 
Cancer form that begins in 
the skin or tissues that 
line/cover internal organs. 
Many further subtypes. 
Common type (85 out 





Cancers that start in the cells 
of the immune system. 
Uncommon form (5 
out of 100 cases 5%). 
Leukaemia 
 
Cancer form that initiates 
from the blood forming 
tissues such as bone marrow. 
This can result in the 
production of vast quantities 
of abnormal cells which go 
directly into the 
bloodstream.  
Uncommon (3 out of 
100 cancer cases 3%). 
The most common 
form of cancer in 
children. 
Brain and Spinal 
Cord tumours 
 
These cancers are commonly 
known as central nervous 
system cancers. 
Uncommon (3 out of 
100 cancer cases 3%). 
Sarcomas 
 
Cancer that starts in the 
connective or supportive 
tissues including bone, 
cartilage, fat, muscle or 
blood vessels. 
Uncommon (1 in every 
100 cancers 1%). 




Cancer is commonly triggered by carcinogens or cancer causing agents, which 
damage the deoxyribonucleic acid (DNA). Carcinogens are recognised in many 
forms, radiation from sunlight, toxins in the smoke from pyrolysed cigarettes 
and other toxic chemicals such as alcohol. In addition to these sources 
chemicals within our own bodies such as sex hormones can overstimulate cells 
and provoke the formation of cancers.17 Some viruses such as Hepatitis C can 
also damage DNA. A series of events have to take place for cancer to occur.17  
 
The first stage normally involves damage to the DNA of genes called 
oncogenes. Oncogenes are responsible for the programming of cell behaviour, 
when damaged or mutated the DNA is repaired. If the repair is impossible cell 
death or apoptosis should occur and the cell is eliminated. The genes fail to 
act normally and prevent apoptosis happening, instead the cells are 
encouraged to remain in place and divide. Once normal tissue regulation is 
disrupted tumour development follows.17 
 
1.2.4.Treatment of Cancer 
 
Cancer cells can be treated using a number of different techniques, the 
simplest being surgery to remove the specific growth or complex therapies 
which use radiation or chemicals to destroy specific cells.16,17    The treatment 
of cancer depends upon a number of factors: the type of cancer, the location in 
the body and the form it appears in. The principal aim of a surgical 
intervention is to remove all or some of the tumour while still retaining bodily 
function. As previously stated this is almost impossible in the majority of most 
patient cases.17  
 
Radiotherapy uses localised high energy ionising radiation to reduce the 
tumour size or kill the tumour cells. Patients treated using this medium, are 
exposed to short wavelength radiation in the form of x-rays, gamma rays and 
charged particles. The frequency of the treatment and the strength of the 
radiation dosage are determined by the tumour site and size.   
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Although radiotherapy is suitable for most solid tumour types, and can reduce 
tumour size it does have its disadvantages. The radiation used is not specific at 
only killing cancer cells and can additionally damage normal cells leading to 
potential side effects.23  
 
Chemotherapy utilises chemotherapeutic agents or cytotoxic compounds 
which target and destroy cancer cells.24 Patients who have advanced or 
multiple cancer sites are commonly treated using chemotherapeutic agents. 
The drugs used do have a significant effect on the tumour cells by either 
completely stopping or changing their growth rate.  Their usage however can 
have considerable side effects which include sores of the mouth, nausea and 
hair loss. This disadvantage is partly due to the fact that although the drugs 
used are selective to cancer cells, normal healthy cells which grow and divide 
quickly are also targeted.24 The initial side effects of using cytotoxic 
compounds are less serious, but long term exposure or high dosage can lead to 
allergic reaction, intolerance and possible toxicity. TDM is used to monitor 
long term usage and to confirm that an effective dosage has been prescribed, 
which can minimise the side effects experienced. The effective measurement 
of the drug or its metabolite allows clinicians to intervene if a dosage needs to 
be raised or a necessary antidote given if required. The prescribed drugs are 
commonly given in low concentrations and small doses to prevent adverse 
events occurring. The frequency and strength of the treatment is again 
dependent upon the cancer type, size and location.   
 
It is common practice now for patients to receive combination therapies, such 
as surgery with a programme of either radiotherapy or chemotherapy. In some 
instances, this treatment regime can eliminate cancer or prevent it 
manifesting in a new area of the body.23 Combination therapies also present an 
analytical challenge as any developed method must allow for any potential 
interference from other compounds involved in the treatment of the patient. 
Specific, accurate and reliable results are needed to support TDM.  
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Single methods that can simultaneously detect and quantify all the 
compounds used in some treatments are hard to develop due to the nature 
and characteristics of certain cancer agents. Patients involved in this study 
received Dexanabinol combined with excipients CrEL and ethanol. In addition 
to the primary research compound the patients also receive Dexamethasone, 
Ranitidine and Chlorphenamine to try and prevent potential side effects 
including hypersensitivity. These compounds are chemically different for 
example Dexanabinol is a cannabinoid and CrEL is an oily hydrophobic 
compound. Both compounds can be isolated from EDTA plasma samples but 
require completely different extraction methods. Each method allows for the 
complete removal and purification of a particular analyte, but sadly does not 







2.1. Analytical Separation Theory 
 
A vast range of analytical separation tools exist for the development of 
bioanalytical methods from biological matrices. Commonly used separation 
tools include capillary electrophoresis (CE), gas chromatography (GC), liquid 
chromatography (LC) and more recently ultra performance liquid 
chromatography (UPLC). 
 
Chromatography is the general term for a group of techniques which have the 
ability to separate mixtures into their individual components.25 When 
separated, the evaluation of each component occurs. The main principal 
remains the same for all chromatography techniques; separation occurs when 
the sample is combined with the mobile phase. The mobile phase is a liquid or 
gas which suspends the compounds then carries the sample mixture through a 
structure or stationary phase.26, 27 A stationary phase is typically a chemical 
contained within a tube that has the ability to attract the compound of 
interest from the sample mixture. Each compound within the mixture will 
interact with the stationary phase at a different amount. Compounds that 
interact weakly and do not adhere to the column stationary medium will be 
the first to elute from the column, while those interacting and demonstrating 
strong adhesion will elute at a slower rate eluting last. There are lots of 
different stationary and mobile phases that can be used depending upon the 
characteristics of the mixture needing to be separated.26 Further conditions 
can be changed including the temperature in the stationary phase and pH or 
pressure in the mobile phase. Each characteristic which is altered has an effect 
upon the partition coefficient which is the simple ratio of the concentration of 
a solute in two immiscible or slightly immiscible phases, when it is in 




GC is a powerful chromatographic tool which uses an inert gas as its mobile 
phase typically helium, argon or nitrogen. Samples are injected and vaporised 
on to an analytical capillary column containing the stationary phase, typically 
made of silica and varying in both overall length and internal bore size. The 
column is situated inside an oven compartment which is used to increase the 
temperature gradually or ramped up, this procedure aids the rate of 
separation.28, 29 Typically compounds with a high molecular weight take longer 
to elute from the column and compounds with low boiling points elute first 
and compounds with high boiling points elute last. The gas mobile phase 
carries the mixture through the heated column where it interacts with the 
stationary phase, separates and elutes from the column and diverts into a 
detector. The time it takes for the compound to travel through the capillary 
column from initial injection until elution is called the retention time.29 When 
a compound is detected the detector creates an electronic signal, which is then 
processed by a computer (Figure 4). Many different types of detectors can be 
used with GC and include: mass spectrometry, flame photometry, flame 
ionisation, electron capture and thermal conductivity. The detector used is 
typically related to the sample type and its chemical characteristics.29  
 




LC or HPLC is another chromatographic tool still following similar principle to 
GC, but using a solvent as its mobile phase. The solvent is pumped through 
the system using a high-pressure pump which is controlled by the solvent 
manager.  
An injector introduces the sample to the mobile flow stream which leads 
directly into the analytical column. The analytical column used typically 
appears as a stainless-steel tube and comes in a variety of lengths and packing 
compositions, a common packing material is C18 or octadecylsilane.30 The 
packing material is the stationary phase in the system and is the mechanism 
for separating the mixture of compounds into its components. As the 
components elute from the column a detector is again required to identify the 
compound bands and translate them into signals. A computer translates these 
signals in to a visible form or chromatogram (Figure 5). After the detector, any 
remaining liquid is diverted to a waste reservoir. Detectors which are 
commonly combined with LC are Ultraviolet-Visible (UV-Vis), fluorescence 
and mass spectroscopic. The detector used will relate to the compound of 
interest and its chemical nature.31 
 
Figure 5: Simple schematic of an LC system drawn by Tom Cull 
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Within the last decade, HPLC has led to the development of UPLC systems 
which have the capacity to offer quicker separations and data analysis without 
compromising accuracy or data quality.31 The demand for such analytical tools 
has come from analytical arenas such as pharmaceutical development, clinical 
trials and forensic toxicology where faster analytical data was desired. The 
benefit of faster separation relates to shorter method run time, meaning 
higher throughput of samples when compared to most HPLC run times.30  
Newer UPLC systems also mean improved technology in relation to columns, 
detectors and system hardware. UPLC columns are very different when 
compared to their HPLC counterparts. The column packing mediums are 
reduced also, from 10µm in HPLC to 2.5 µm or smaller in UPLC. Small particle 
columns cannot be used on typical HPLC modules because their pumps 
cannot generate the desired operating pressures which can be in excess of 
13,000 psi.30 Downsides to the advanced technology are the initial cost of the 
equipment, the column lifespan when used at high pressures and the internal 
bore size of the tubing used is less forgiving than that of a conventional HPLC 
system.  Increased working pressure and reduced tube bore sizes could 
potentially lead to blockages of the system if clean extracts are not used.  
Additionally, regular preventative maintenance is also required to ensure the 
chromatographic system works robustly. 
2.1.1. Detectors 
Many different types of detector exist and the three most commonly used with 
LC are UV-vis, fluorescence and mass spectrometry including tandem mass 
spectrometry. 
A UV-vis detector focuses upon the visible and UV regions of the 
electromagnetic spectrum around the 200-800nm (Table 3 and Figure 6). The 
technique is useful for determining heavy metals and organic materials in 
water and as a quality control technique in the dye, ink and paint industry.  
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Samples are exposed to a beam of electromagnetic radiation (ER) from a light 
source. The spectrometer has two light sources, a high intensity tungsten bulb 
which provides the visible region and a deuterium lamp for the UV region. 
These lamps together provide the entire range of the instrument.  If the 
wavelength range is used, the source is changed over at the designated point. 
The radiation from the source is split into two equal intensity beams.  
One beam is passed through a dilute sample solution and the other passes 
through a pure solvent acting as the reference against which the first is 
compared after transmittance. Advantages of UV-vis include its wide linear 
range, but disadvantages are its lack of selectivity and sensitivity.31          
Figure 6: Regions of the Electromagnetic Spectrum 
(http://arstechnica.co.uk/science/2016/03/james-webb-telescope-details/) 
Region Wavelength (nm) 
Infrared (IR) 800 Ȃ 50,000 nm 
Visible 400 Ȃ 800 nm 
Ultraviolet (UV) 190 Ȃ 400 nm 
Table 3: Identified regions for visible, infrared and ultraviolet from the 
electromagnetic spectrum. 
A Fluorescence detector focuses upon a narrow window of only 200-700nm 
(see Table 3 and Figure 6). The system works on a slightly different principle.32 
Molecules whose electrons have absorbed ER and have been raised to a higher 
energy level soon expel some of the energy and return to their ground state.  
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However not all the molecules lose all their energy, only losing some of the 
energy by non-radiant routes. The remaining energy that is then emitted as ER 
and this is fluorescence.   This means that because only some of the absorbed 
energy is emitted, the wavelength of the fluorescent light is longer than the 
absorbed light (longer wavelength = lower energy). 31 
So, a fluorescent molecule has two spectra; an emission and an absorption or 
excitation spectra. The wavelengths of the emission and absorption are two 
different values. The wavelengths values are measured in nm and the 
difference between the two can be compared using a tool known as Stokes 
shift. The existence of this tool means that emitted light can be detected 
against a low background. Advantages include higher sensitivity looking at 
two wavelengths, but its disadvantages are that only 10-15% of compounds 
actually fluoresce and may require coupling with fluorescent dye. Further 
negative points include quenching that can occur when other substances in a 
mixture interfere with the energy transfer.33    
2.1.2. Mass Spectrometry 
 
Mass Spectrometry is a sensitive and specific technique which offers valuable 
information about the molecular weight of a compound and potentially its 
chemical structure.   Mass spectrometry utilises the process of the ionisation 
of a sample, where positive and negative ions are produced. There ions are 
then accelerated into a high vacuum region where electric and magnetic fields 
are present.34  
 
The fields serve to deflect and focus the ions to the detector. The fields can be 
controlled and adjusted so to allow different ions to reach the detector. The 
resulting image of the detected ions is known as a spectrum and is a series of 




From this the mass to charge (m/z) ratio can be assigned. Typically, different 
compounds can be identified by the specific pattern of peaks, which some 
refer to as the chemical fingerprint. The main components of an MS are the 
interface samples inlet, an ionisation source, a mass analyser and an ion 
detector (Figure 4).34 
 
2.1.3. Tandem mass spectrometry 
 
Tandem mass spectrometry is now increasingly used routinely in the clinical 
biochemistry laboratory in the measurement of various analytes. The major 
aspects include the ionisation of the compound either in a positive or negative 
mode. The ionised compounds are detected and separated in the first mass 
spectrometer as molecular, precursor or parent ions.34 These are then passed 
through a collision cell where fragmentation takes place resulting in the 
formation of many daughter or fragment ions. These are separated in the 
second mass spectrometer according to their mass/charge (m/z) ratio and 
passed into the detector for detection and determination of the intensity of 
the signal, a measure of the concentration of the compound. A schematic 
diagram showing the principles of tandem mass spectrometry is shown in 




Figure 7: Schematic diagrams of tandem mass spectrometry indicating the 
individual components. Image belongs to Waters, Manchester, but given 
permission to use in this thesis. 
 
Figure 8: Tandem mass spectrometry schematic including an ESI interface. Image 





Many forms of interface source are present in the modern laboratory setting, 
but the two most popular types are electrospray ionisation (ESI) and 
atmospheric pressure chemical ionisation (APCI). Although ESI and APCI are 
different techniques they can still be achieved using the same instrument 
source. However, they do require different components to achieve the same 
chemical objective. 34  
 
In ESI mode, ions are generated from the solution entering the inlet. The 
sample is dispersed via the capillary in the nebuliser, which has a high-energy 
potential applied to it of around 3-5 kV. The high-energy field causes the 
solution to form a mist of highly charged droplets. The droplets reduce in size 
as the solvent evaporates and the electric charge density on the surface 
increases, this effect is called the Coulomb explosion.34 The droplets then 
further subdivide when they are exposed to a potential and pressure gradient. 
Positive and negative ions are separated using a positive charge which is 
applied to the capillary tip. Positive ions because of their nature then repel the 
capillary and form a cone called a (Taylor cone) where they experience 
reduced surface tension due to their mutual repulsion of like charges (Figure 
9).34 The combination of solvent evaporation and charge density eventually 
causes the ions to be ejected from the dropletǯs surface. During the final stage, 
it is believed that the analyte abstracts one or more protons from the solvent 
to give a positively charged gas phase ion. The ion is directed into the mass 
analyser using electrostatic direction, where an opposite charge to that used 
on the capillary is applied to the skimmer cones resulting in the redirection of 
analyte ions.31   
 
Ion generation from analyte solutions follows two path directions: charge 




Ion formation in positive mode:   
R-NH2 + H+ ĺ R-NH3+ (protonation) 
C6H12O6 + Na+ ĺ C6H12O6 Na+ (adduct formation) 
 
Ion formation in negative mode:  
R-COOH ĺ R-COO- + H+ (deprotonation) 
C6H12O6 ĺ + A- ĺ C6H12O6 A- (adduct formation, A=Cl-, CH3COO-, HCOO-.) 
 
 
Figure 9: ESI schematic showing the main components and sample conversion 
into ions including the Taylor cone and the Coulomb explosion.  Image drawn by 
Tom Cull, replicated from Ǥǡǯ	
Toxicology, ed. S. Jickells and A. Negrusz 35. 
 
 APCI as previously mentioned can be undertaken using the same instrument 
source used for ESI, but it is reconfigured with the addition of a corona 
discharge pin.  
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ESI promotes the production of ions by evaporation, but APCI differs because 
it uses chemical ionisation (CI), where the solvent acts as the reagent gas to 
ionise the sample.31 The eluent enters the interface again using the same 
capillary system used in ESI, but the major difference is the way the in which 
the aerosol is formed. The sample emerges from the capillary and is instantly 
heated by an inert nebulising gas causing the liquid to evaporate. The corona 
discharge pin is placed directly in the path of the heated region of the source. 
The corona pin again has a high-energy potential applied to it which can 
ionise solvent droplets using its electrical discharge. A gas plasma is produced 
by the chemical ionisation and proton transfer (Figure 10). Ions that promote 




Figure 10: APCI schematic showing the main components and how ions are 
formed. Image replicated by Tom Cull from http://www.chm.bris.ac.uk/ms/apci-




The key concept to understand about APCI is how the reagent gas forms in 
both positive and negative modes.34 The positive and negative reagent gas 
formations are shown below: 
 
Reagent gas in positive mode: 
N2+. + H2O ĺ N2 + H2O+. 
H3O+ + Mĺ MH+ + H2O (protonation) 
 
Reagent gas in negative mode: 
H2O + e- (cold electron) ĺ H2O-Ǘ ĺ HO- + HǗ 
M-H + HO- ĺ M- + H2O (deprotonation) 
 
 APCI lacks the sensitivity of ESI, but can be used in the application of 
molecules such as neutral drugs which will not easily ionise using ESI.34  
ESI however is useful for analysing compounds that have large masses, but is 
susceptible to over contamination from previous experiment residues and is 
not easy to clean. 
 






Analytical techniques used Simplicity of 
method - 
disadvantages 
1996 J.M. Challinor GC-MS and Curie-point 
pyrolyser/  






HPLC / Fatty acid extraction/ 
derivatization 
Long procedure 





Colorimetric dye binding 
assay/protein precipitation 




1998 E. Brouwer Colorimetric dye binding 
assay/protein precipitation 






Colorimetric dye binding assay/ 
protein precipitation 
Relies on dye 
binding 
2000 L. van Zuylen HPLC with UV detection / dye 
binding assay 
Relies on dye 
binding 






Pyrolysis mass spectrometry 
compared against HPLC / Fatty 
acid extraction / derivatization  
Equipment not 
readily available 
2004 H.J.G. Desiree 
van den 
Bongard 
Liquid scintillation counting Only suitable 
for determining 
unbound 
fraction of drug 




oils not plasma 
2009 V. Coopman GC-MS and LC-MS/MS / SPE  




2013 V. Vijaya 
Bhaskar 
LC-MS/MS / protein 
precipitation 
Only specific to 
PEG 
Table 4: Summary table of publications and journal papers focussing upon the 
measurement of CrEL in human plasma and other matrices, specifically CrEL. 
 
The measurement of fatty acids has been inv ? ? ? ?ǯǡ
acids such as CrEL were looked at in later years.  The first recorded journal 




This paper describes some of the extraction techniques appropriate for the 
removal of fatty acids from a blood matrix, which include alcohol/ether 
extraction, saponification using a suitable alkali and a technique called a 
nephelometer. 36 
 
A nephelometer is an instrument for measuring the size and concentration of 
particles suspended in a liquid or gas, especially by means of the light they 
scatter. During these early experiments, it was also established that it was 
important to have pure uncontaminated solvents such as chloroform which 
should be free from moisture and alcohol. An addition point stated in the 
paper is that accurate determinations cannot be made if the standard and the 
test solutions are more than 30% apart, showing that even then analysts had 
grasped the concepts of validity and reproducibility.36 Later papers started to 
use analytical equipment to perform similar experiments previously 
undertaken using basic tools.     
 
The equipment available to these early scientific pioneers was limited. 
Chromatography was basic with only thin layer chromatography.  
The findings of these scientific pioneers led to the development of future 
methods, which when combined with advanced technology led to further 
breakthroughs into lipid profiling. 
 
Challinor et al (1996) developed a simple pyrolysis GC-MS method for 
profiling fatty acids in a range of vegetable oils and animal fats. The precise 
equipment used was a Curie- point pyrolyser connected to a Hewlett-Packard 
gas chromatograph equipped with a flame ionisation detector (FID). Samples 
were run in duplicate using flattened pyrolysis wire, which after the addition 
of aqueous tetramethyl ammonium hydroxide (TMAH) was placed directly 
into the pyrolyser to act as a high temperature reactor converting the 
triglycerides into fatty acid methyl esters (FAME). The paper discusses in 




The steps include saponification using a suitable alkali, and acid catalysed 
methylation using boron trifluoride followed by analysis using GC. Although 
this method is very quick and simple, sadly the equipment is very uncommon 
and the method only profiles fatty acids rather than quantifying them.37     
 
Sparreboom et al (1996) developed a different method using HPLC with ultra 
violet detection (UV), which focuses upon the quantitation of the major 
component of CrEL, ricinoleic acid. The internal standard used was Magaric 
acid a saturated fatty acid.  The samples were extracted using the following 
procedure: saponification using alcoholic potassium hydroxide (KOH), lipid 
isolated using chloroform and finally derivatization using 1-naphthylamine. 
The original abstract of this paper described a simple method, however the 
actual method when viewed in detail has many separate steps including 
sample preparation and involves the uses of some highly carcinogenic 
chemicals, Ʉ-naphthylamine. The use of HPLC often means long 
run times and in this assay each sample takes at least 35 minutes in order to 
retain good resolution even though the analyte elutes at 10 minutes.38 
 
Sparreboom et al (1998) developed another assay utilising Colourimetric dye 
binding. This technique relies upon the binding of Coomassie brilliant blue G-
250 to CrEL and in doing so causing a shift in the absorption maximum from 
465 to 624 nm. The samples do require sample preparation, drying and 
reconstitution, before the final step where the dye can be added. Specifically, 
50 ρl of plasma was added to 500 ρl of acetonitrile in the sample 
deproteinizing step. Samples and calibrators were extracted in duplicate, and 
each single extract analysed twice. QC samples however had quintuplicate 
measurements taken. The assay does have selectivity, but according to other 
written papers using the same method it may have interference from non-
ionic surfactants such as Triton x-100 and Tween 80. After further testing, 




Potential problems with this assay relate to its detectable range which is only 
0.05 Ȃ 1.00% (v/v), the range should be greater to allow for higher sample 
concentrations. Further dilution of samples is not mentioned and would need 
to be undertaken during the sample preparation steps. This method does 
appear simple, but still relies upon specific equipment in the form of an 
automated microplate-absorbance reader.39 
 
 A discussion in this paper reviews alternative methods previously used to 
measure CrEL including reverse HPLC which it refers to as complex, expensive 
and time consuming when compared to a rapid extraction followed by 
Colorimetric analysis. However, something overlooked in this method is the 
variability of acetonitrile quality and the potential contamination from 
purified water. The grade of solvent used is of particular importance during 
analysis, especially for Colourimetry where the solvent used can influence the 
shape and quality of the spectrum. An HPLC grade was used in the assay and 
supplied by Sigma Aldrich, but other HPLC grades from different suppliers 
could have been tested and compared to confirm any possible quenching or 
enhancement. Water quality can also affect Colorimetry, depending upon the 
type of water purifying system used and the cartridge type.  
 
Some cartridges have the potential to leave ion-exchange resin fragments in 
the cleaned product, which can lead to non-specific absorption at low 
wavelengths 40.     
  
Brouwer et al (1998) also uses a Colourimetric dye binding assay, but states 
that the assay of Sparreboom et al (1998-A) has a major disadvantage which is 
its lack of linearity. The plot of the peak wavelength of CrEL, versus the 
concentration of the CrEL is non-linear. Brouwer et al (1998) has shown in this 
paper that the nonlinearity is associated with a decrease in the free dye 
concentration and a reduction in complex formation by increasing CrEL 
concentration. This assay also covers the wider range of 0.500 Ȃ 10.0 ρl/ml and 
samples can be analysed as single extracts rather that in duplicate.  
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The method also uses a different version of the typical Coomassie dye, using 
the red form which turns blue when binding to CrEL.41 The method is more 
specific and does cover a greater range, but still uses the automated 
microplate-absorbance reader. The authors of this research still make no 
provision for any potential interferences related to acetonitrile grade between 
different suppliers. In addition deionised water is used rather than double-
distilled water, which still could contain ion-exchange resin particulates which 
could lead to non-specific absorption at low wavelengths.   
 
Sparreboom et al (1998-B) published a later paper still using the Colourimetric 
dye binding assay, but this time the aim was to establish how quickly the 
human body eliminates CrEL. Patients receiving the taxane Piclitaxel as part of 
their treatment plan had plasma samples collected on regular intervals during 
drug infusion. This is a similar method to a previous paper by Sparreboom et 
al (1998-A), but using some of the modifications suggested by Brouwer et al 
(1998).  A further addition not mentioned in previous Colourimetric assays is 
how to deal with samples above the analytical range, they are diluted in drug 
free plasma and reanalysed.  
 
This assay still utilises the automated microplate-absorbance reader, but did 
establish that CrEL is a slow clearance compound remaining in the body for an 
extended time within the central plasma compartment.42 This paper has some 
interesting findings regarding CrEL, but is still reliant upon the automated 
microplate-absorbance reader. The potential problems of acetonitrile still 
remain and are not allowed for 40.  
 
Zuylen et al (2000) focussed again upon the chromatographic principles of 
HPLC to understand the clinical PK of CrEL. This method differed from 
Sparreboom et al 1 because UV detection was used to analyse piclitaxel and 
CrEL, levels were again established in plasma using Colourimetric dye binding. 
The collected data was then applied to response models to determine the 
relationship between the two analytes.   
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The determined relationship shows that as CrEL concentration increases the 
speed at which piclitaxel is expelled from the body slows down.43 This paper 
again has useful findings, but still uses Colorimetry as its main analytical tool. 
 
Gelderblom et al (2001) is a discussion paper around the usage of CrEL as an 
excipient vehicle and as a drug formulation additive. Throughout the paper no 
analytical procedures are discussed, but important clinical details are 
discussed around the biological effects of CrEL.10 This paper outlines the 
importance of extensive testing when developing drugs and their formulation 
compounds. 
  
Ghassempour et al (2003) returned to the initial technique of pyrolysis Ȃ mass 
spectrometry (Py-MS). However, this time it was specific to the determination 
of CrEL in both drugs and plasma and also facilitated the comparison of  
Py-MS and HPLC. For Py-MS sample underwent a simple preparation step 
before being dried and analysed in triplicate. The sample preparation for 
HPLC analysis was more detailed and included saponification, lipid removal 
and reconstitution steps. The conclusion of the methodology comparison was 
better for the Py-MS method than the HPLC method.43  
 
The sample volumes required, the extraction times and the reliance on highly 
carcinogenic chemicals, gave Py-MS a number of advantages over the HPLC 
method. However, the Py-MS equipment is not readily available and has 
limited usage in a clinical setting.  
 
Desiree van den Bongard et al (2004) used ultra-filtration and liquid 
scintillation counting to determine the unbound fraction of piclitaxel in 
human plasma.44 This paper does comment on the usage of CrEL in relation to 
piclitaxel concentration. This technique might not be a standard practice used 




Yamamoto et al (2008) looked at ricinoleic acid in both common vegetable oils 
and oil seed using GC-MS. The method used a common FAMES extraction to 
isolate the ricinoleic acid before finally derivatising the extract to be analysed 
on the GC-MS. The method was successful in detecting ricinoleic acid, but the 
authors were unaware of how many vegetable oils contain ricinoleic acid. Its 
application is suitable for industries such as food and cosmetics where trace 
quantities are required.45     
 
Coopman et al (2009) is a case report from Belgium on the death of a man who 
injected himself with a castor bean and acetone extract. Ricinine is a 
piperidine alkaloid toxin with a low molecular weight which is present in the 
castor leaves and beans. The paper is particularly interesting because it utilises 
two techniques in the determination of the compound Ricinine. Solid phase 
extraction (SPE) in combination with GC-MS in full scan mode was used to 
identify the compound and SPE in combination with LC-MS/MS in positive 
mode was used to confirm Ricinine in three biological matrices. The methods 
discussed in this paper appear to be effective and even mention the detection 
of ricinoleic acid as the sample pre-treatment did not completely remove the 
castor oil present in the samples. This is one of the first papers to discuss the 
use of LC-MS/MS, for the detection of a CrEL related compound.46  
The major disadvantage of this method is the uses of SPE as a sample 
preparation step. SPE offers high recovery, but is normally an expensive 
consumable.   
 
At this stage, no other methods existed that involved CrEL analysis and HPLC 
was the most advanced technology used. The assay developed from this 
research was used in 2011 and was at that time was the first non-published 
method for the measurement of CrEL using LC-MS/MS. However, by 2014 
when the study ended another researcher Bhaskar et al had already published 




Bhaskar et al (2013) used LC-MS/MS with atmospheric pressure chemical 
ionisation (APCI) to measure CrEL in rat plasma. The sample extraction stage 
is very rapid and uses a polypropylene 96 well plate, which allows for small 
sample volumes and reduced usage of glass tubes which are commonly an 
expensive medium.47 The disadvantages of this method are firstly it measures 
free Polyethylene glycol (PEG) which only makes up 7% of CrEL, so it does not 
focus upon the main constituent of CrEL. Secondly the method has only been 
used on rat plasma, no human plasma appears to have been tested. Many 
formulations routinely used contain PEG, so the specificity of CrEL in human 
samples could be compromised and the analysed data values could be 
significantly greater or invalid due to this unforeseen internal contaminant. 
 
In conclusion, the literature indicates that only a fraction of instruments have 
been used to measure CrEL and other compounds found in the fatty acid 
species. The majority of the sources reviewed have a strong links to the use of 
colorimetric equipment combined with use of the dye agent Coomassie Blue 
which binds to the CrEL compound.39, 41, 42 Most of the methods discussed seem 
to have major pitfalls, due to either a complicated or long extraction procedure 
or reliance on dated or uncommon equipment.  
 
The number of extraction methods that did not involve Coomassie Blue and 
colorimetry were limited, but the original paper by Challinor et al, mentioned 
the FAME extraction principles.37 After further research around this topic a 
paper from Burdge et al (2000) presented a potential method for the extraction 
of fatty acids from plasma.47 
 
The sample preparation steps included lipid isolation using LLE with 
chloroform: methanol: BHT and sodium chloride, the eluted solvent fraction 
was collected. The remaining protein disc was further extracted again using 
chloroform: methanol: BHT and sodium chloride, the previous collected 
faction and the second fraction were combined and then dried under nitrogen.   
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The dried extracts were then reconstituted in chloroform before being added 
to SPE cartridges (aminopropyl silica column 100 mg). Separate columns were 
used for different fatty acid species, some needed preconditioning with 
methanol while others required hexane. The pre-sample preparation steps up 
to the drying down of the extracts could be applied to the isolation of CrEL 
from human plasma.48   
 
2.2.1. Extraction techniques 
 
All types of sample matrix will generally require some form of sample pre-
treatment before they can be analysed on an instrument platform. Many pre-
treatment methods exist and each is best suited to a particular form of matrix. 
The principal aims of all sample pre-treatments in the context of 
chromatography are to provide an aliquot that recovers the majority of the 
analyte while being free of interferences, it will not damage the analytical 
column and is in a compatible form to be separated and detected on the 
intended platform.28, 49  
 
Different pre-treatments available for biological liquid samples are protein 
precipitation (PP), liquid-liquid extraction (LLE) and solid phase extraction 
(SPE). 
 
PP is a common extraction procedure involving a solvent, acid or base which is 
added to the biological matrix. Commonly used examples include zinc 
sulphate, methanol or acetonitrile. The solution is normally agitated and 
Ǯǯm a 
pellet. The supernatant layer above the pellet should contain the analyte and 
can be injected directly into some analytical systems such as LC-MS.  This 
particular extraction method is quick, non-expensive and uses relatively 
simple equipment. However, it only removes some of the biological 





LLE is the application of separating analytes from interferences using two 
immiscible liquid phases, one aqueous and the other a solvent (Figure 11). 
Analyte compounds which are hydrophilic in nature will partition themselves 
in the polar aqueous phase, while the hydrophobic ones will be attracted to 
the organic solvent. The sample is added to the container, the aqueous phase 
is added followed by the solvent.28,50  
 
The mixture is again agitated using a mechanical shaker and is then 
centrifuged to separate the defined layers (Figure 12). The analyte at this stage 
should have partitioned in the solvent phase, leaving any biological material in 
the aqueous layer. This form of extraction is also quick to undertake and 
removes more biological interferences than PP, but consumes vast quantities 
of organic solvents. Depending upon the nature of the analyte further steps to 
dry and reconstitute may be necessary. LLE is also suitable for compounds 
which are non-volatile and heat sensitive.50  
 




Figure 12: Schematic of the LLE extraction process 
 
SPE is another form of sample preparation which uses solid and liquid phases 
to remove the analyte from the biological matrix. The application is typically 
four steps which are: conditioning, sample loading, washing and eluting 
(Figure 13).  
 
The SPE column contains a sorbent disc, which is chemically able to retain the 
analyte while allowing all other biological material to be washed through. The 
column must be conditioned/wetted using a suitable solvent. The biological 
sample can then be added to the column, as the sample flows through the 
column the sorbent binds to the analyte allowing any other material including 
proteins to be washed off and elute the column. Finally, a suitable elution 
solvent is then added which has a stronger affinity to the analyte removing it 
from the sorbent. At this point the sample may require further steps to dry 
and reconstitute. SPE offers high recovery of analytes, but can be expensive 
and labour intensive if performed manually.  
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The technique can be automated and is sometimes available as an on-line 
component on instrument allowing samples to be extracted and injected 




Figure 13: Schematic of SPE analysis steps including: conditioning, sample 
addition, washing and elution. 
2.3. Current equipment in the laboratory 
 




Liquid chromatography was performed using a (Waters, Manchester, UK) 
Acquity UPLC (serial number: L08UPH779M) with a HSS T3 column (100 mm 
x 2.1 mm, 1.8 Pm) (186003539) also from Waters UK.                                          
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The Acquity UPLC system consists of an auto sampler, a binary solvent pump 
an injection loop and a column compartment (Figure 14).  The Acquity is a 
high pressure, ultra performance liquid chromatography system. The high 
pressure generated up to 15,000 psi compared to other liquid chromatography 




Detection of analytes was performed using a tandem quadrupole mass 
spectrometer also a Waters instrument, a Quattro Premier XE (serial number 
VAB 1255). The instrument contains a Z-Spray ionisation source and a T-wave 
collision cell. The high speed scanning T wave technology of the Quattro 
Premier makes it suitable to ionise and scan the compounds presented to it at 
the high pressures of the Acquity. Ionisation is achieved by electrospray in 
either a positive (ESI+) or negative mode (ESI-). A photograph showing the 













Figure 14: the Acquity and Quattro Premier LC-MS/MS systems. Refer to 






Operation of both the Acquity and the Quattro Premier XE, was controlled 
through Masslynx 4.1, supplied by Waters. Data processing was achieved with 
Targetlynx. 
 




Gas Chromatography (GC) was performed using an (Agilent, West Lothian, 
UK) 6890N Network GC system (serial number: CN10542008). The GC uses a 
DB 17 MS (Agilent Technologies) column (15 M x 0.25 mm, o.25µm). The GC 
system also consists of 7683B series Injector (serial number: CN55330443) and 
a 7683 series Auto sampler (serial number: CN55137795). The carrier gas 
employed by the system is helium.  The GC system is joined to a Mass 
Spectrometer (MS) which enables the detection and identification of ions 
within the samples analysed. The Agilent GC system is a state of the art gas 





Mass Spectrometry (MS) was performed using an (Agilent, West Lothian, UK) 
5975 Inert mass selective detector (serial number: US52420874).  









The GC-MS system was controlled using the Agilent MSD Chem Station 










3.1.1.1. Tandem mass spectrometry was performed on the Quattro 
Premier XE (serial number VAB 1255) Waters Ltd. 
3.1.1.2. Liquid chromatography was performed by the Acquity UPLC 
(serial number DO9 UPA 880M) Waters Ltd. 
3.1.1.3. Column: Acquity UPLC® HSS T3 1.8 µm, 2.1 x 100 mm column 
Part No: 186003539, Lot No: 0114391761 
3.1.1.4. Techne Driblock - FDB03AD (serial number 154625 - A) and 
Sample Concentrator Ȃ FSC400D (serial number 155395 - 2) 
3.1.1.5. IKA Vibrax VXR Basic - mechanical shaker (serial number 
01.798796) 
3.1.1.6. Beckman Spinchron ? DLX Centrifuge (serial number 
GHY98F29) 
 
3.1.2. Reagents / Solutions 
 
3.1.2.1.        Cremophor EL 500 g standard (product number: C5145-
5ooG) was purchased from Sigma-Aldrich, UK. 
3.1.2.2. Ricinoleic acid 1 g standard (product number: R7257) was 
obtained from Sigma-Aldrich, UK. 
3.1.2.3. Mobile Phase (UPLC) and system reagents 
 
Methanol (LC-MS grade)    Fisher, UK 
  Methanol (HPLC grade)    Fisher, UK 
  Ethanol (HPLC grade)             Fisher, UK 
  Acetonitrile (HPLC grade)                                       Fisher, UK 
  Isopropanol (HPLC grade)                                       Fisher, UK 




Millipore deionised water Ȃ filtered daily to a recommended 
quality of 18.2 ȹǤ      
 
3.1.3. Extraction Solvents and chemicals 
 
  Hexane (HPLC grade)                                   Fisher, UK 
  Chloroform (HPLC grade)                Fisher, UK 
        Methanol (LCMS grade, part no: 34966)     Sigma, UK 
             Ethanol (HPLC grade)    Fisher, UK 
Diethyl ether (HPLC grade)   Fisher, UK 
  
Millipore deionised water Ȃ filtered daily to a recommended 
 崃?Ǥ ?ȹǤ 
 
The water purity value and grade relate to the removal of 
bacteria and possible particles from the deionizer.   
 
Butylated hydroxytoluene (BHT)   Sigma, UK 
Molecular sieves (AW-300)    Sigma, UK 
Sodium chloride     Fisher, UK 
Sodium hydroxide      Sigma, UK 
Sodium sulphate     Sigma, UK 
 
3.1.4. Working Reagents 
 
   Mobile phase A2: 0.1% Formic Acid in DW 
 








1. Chloroform: methanol (2:1,v/v) BHT (50mg/L): 
50mg of BHT was accurately weighed out, 
667ml of chloroform and 333ml of methanol 
were mixed.  The materials were then 
added together and mixed thoroughly.  The 
resulting solution was stable for 6 months 
at room temperature. 
 
2. 1 M Sodium Chloride in deionised water:  
58.44g of sodium chloride was added to 1 
litre of deionised water.  The produced 
solution was stable for 6 months at room 
temperature. 
3. 2 M Sodium hydroxide in methanol (LC-MS) grade 
(40g in 500 ml):  
40g of sodium hydroxide pellets was 
accurately weighed and added to 500ml of 
LCMS grade methanol.  The prepared 
solution was thoroughly mixed and heated 
at 50°C in an ultrasonic bath until all the 
pellets had dissolved.  The resulting 











3.1.5. Materials and consumables  
 
3.1.5.1.          Fresh frozen plasma (FFP) was supplied by a 
Haematology Department, in Hampshire. 
3.1.5.2.  10 ml glass LabCo tubes were obtained from Fisher 
Scientific, UK. 
3.1.5.3.  Pyrex Ȃ disposable 12 x 75 mm glass culture tubes (LP4), 
glass Pasteur pipette and Chromacol Ȃ glass analysis vials and 
crimp caps were also bought from Fisher Scientific, UK. 
 
3.1.6. Sample Preparation 
 
Cremophor (Polyoxyethyleneglycerol triricoleate 35), undergoes alkaline 
hydrolysis to form ricinoleic acid which is measured by Liquid 
chromatography tandem mass spectrometry (LC-MS/MS). Test samples were 
prepared by spiking Cremophor into fresh frozen plasma (FFP) and extracted 
using chloroform: methanol Lipid extraction procedure as shown below. 
 
3.1.7. Preparation of Cremophor Standard Curve  
 
3.1.7.1.   Cremophor EL stock (Ready to use) Stored in lockable 
cupboard at room temperature. 
   
3.1.8. Preparation of Top Standard (20 µL/ml) 
 
3.1.8.1. 2ml of cremophor EL stock was added to 98ml of FFP and 
thoroughly mixed using a magnetic stirrer at room 
temperature at a constant speed until the lipid cremophor 








3.1.9. Working standard curve 
 
3.1.9.1. Double dilute 1ml 20 µL/ml mixed top standard with 1 ml FFP 
in a series of LabCo tubes to produce a range of standards of 
the following concentrations: 10, 5,2.5, 1.25, 0.625,0.313 µL/ml. 
Vortex mix briefly. Previous pharmacokinetic studies of the 
disposition of Cremophor EL after infusion of Paclitaxel an 
anticancer drug shows that the concentration of Cremophor 
EL rarely peaks beyond 10 µL/ml.  
 
3.1.10. Preparation of Samples for Analysis 
 
Before running the assay it was important to ensure that a sufficient stock of 
sodium sulphate columns were made (see 3.1.10.1). 
 
3.1.10.1. Column preparation 
 
Sodium sulphate columns were made from glass Pasteur pipettes, cotton wool 
and sodium sulphate crystals (Figure 16). The cotton wool acted as a plug to 
prevent the crystals from leaving the pipette. Only a pinch of cotton wool was 
required and this was carefully pushed inside the glass shaft to the neck of the 
pipette. The cotton wool plug was gently eased down to the neck of the 
pipette using a thin spatula. Care was taken not compact the cotton wool plug 
as this could have created problems during the extraction process.  
To each glass Pasteur six spatula scoops of sodium sulphate crystals were 
added. The columns were stored in an airtight container away from moisture 
with a silica desiccant. The sodium sulphate used in the columns acted as a 
desiccant. The purpose of the desiccant is to remove any remaining water left 





Figure 16: Sodium sulphate columns.  Image on right shows column with cotton 
wool bung and wool with sodium sulphate.  Image on left shows prepared 
columns. Refer to comment in declaration regarding photographs. 
  
50µL plasma / QC/ Standard samples were added to a 10 ml LabCo tube and 
vibra-mixed. 
 








x 5 mls of Chloroform: Methanol (2:1,v/v) with BHT (50mg/L), and 1 ml 
sodium chloride were added to the prepared samples and mechanically 
shaken for 5 minutes at 1000 rpm. (Figure 17 and Figure 18 ) 
 
 
Figure 17: 10 mL glass tubes containing 50 µl plasma, 5 mL chloroform:methanol: 






Figure 18: 10 mL glass tubes after mechanical shaking for 5 minutes at 1000 rpm. 
Refer to comment in declaration regarding photographs. 
x The samples were then centrifuged for 10 minutes at 3000 rpm. Two 
defined phases were then visible. Figure 19 
 
 
Figure 19: 10 mL glass tubes after centrifugation at 3000 rpm for 10 minutes. Two 
layers are clearly defined layers with a protein disc sandwiched between the two. 




x The lower phase was collected using a glass Pasteur pipette and 
transferred to a 10 ml Labco tube. When extracting the lower phase, the 
tube was tilted slightly to allow the glass pipette to slip past the upper 
phase and protein band. The collected lower phase was then processed 
using sodium sulphate columns. Sodium sulphate columns were 




x The column was conditioned with 1 ml diethyl ether, the ether was 
allowed to drain to waste in a beaker. The sample was the added to the 
conditioned column to collect the filtrate in a 10 ml LabCo tube. The 
columns were washed with a further 1 ml diethyl ether and collected.   
x The filtrate and ether mixture was then evaporated using a gentle air 
flow in a laminar flow fume cabinet. This stage took approximately 30 
minutes. 
 
Release of Ricinoleic acid 
 
x To each 10 ml LabCo tube, 2 ml of 2 M sodium hydroxide in methanol 
was added and mechanically shaken for 5 minutes at 1600 rpm.  
x A further 2.5 ml of deionised water and 2.5 ml of hexane was then 
added. This was mixed thoroughly and the layers allowed to settle. The 
supernatant phase containing ricinoleic acid was transferred to a glass 
(LP4) tube using a Pasteur pipette.   
x The supernatant was then evaporated using a gentle flow of air in a 









x 500 µL of Ethanol was added to each dry eluate, it was then vortex 
mixed and then 300 µL was transferred to glass analysis vials (auto-




At the start of the development process a Gas Chromatography Mass 
Spectrometry (GC-MS) method was tried (Figure 210 and Figure 21). The GC-
MS was fitted with a lipid specific column a (DB 17 MS) and the GC-MS 
parameters used are present in appendix 1.  
 
 




Figure 21: NIST (National institute of Standards and Technology) Library 
identification tool-identifying CrEL during the first analysis run. 
 
The sample preparation involved a chloroform-methanol extraction, 
hydrolysis using sodium hydroxide and methylation using boron trifluoride 








GC-MS Cremophor assay extraction protocol 
 
Cremophor Stocks 
Original cremophor stock = 20 µl/mL 
Add 2 mL of 20 µl/mL cremophor to 98 mL FFP = 20 µl/mL in FFP(1x QC + 1x 
STD). 
Dispense out 100 mL of QC or STD into 95 x 1 mL aliquots of 20 µl/mL 
cremophor. 
Using 1 mL of 20 µl/mL cremophor, dilute out to form 0.5, 1.0, 2.0, 5.0, 10.0 
µl/mL of cremophor in 1 mL FFP. 
 
Lipid Extraction 
x Add 100 µl of sample/standard plasma to a 10 mL glass tube, add 100 µl 
of 0.1 mg/mL internal standard. 
x Add 5 mL of chloroform : methanol (2:1, v/v) with BHT (50 mg/L). 
x Add 1 mL of 1M sodium chloride. 
x Mix mechanically for 5 minutes at 1000 RPM. 
x Centrifuge at 3000G for 10 minutes. 
x Collect lower phase with Pasteur pipette and transfer to another 10 mL 
tube. 
x Make solid sodium sulphate columns using more glass Pasteur 
pipettes. 
x Pre- wash columns with 2 mL of diethyl ether, drain into a waste 
beaker. 
x Apply sample to column and collect into another 10 mL tube. 
x Wash column with 2 mL of diethyl ether, collect in sample tube. 
x Dry under stream of air (approximately 30 minutes). 
Release of Fatty Acid  
x Add 2 mL of 2M sodium hydroxide in methanol (8 g in 100 mL). 
x Incubate at 100 °C for 1 hour. 
Fatty acid Derivitisation 
x Add 2ml of 25% borontrifluoride solution in methanol 
x Incubate at 80 °C for 1 hour. 
x Add 2.5 mL of deionised water and add 2.5 mL of Hexane. 
x Mix mechanically for 2 minutes at 1000 RPM. 
x Collect supernatant phase with FAME into a 10 mm LP4 tube. 
x Dry under stream of air (approximately 15 minutes). 
x Reconstitute in 100 µl hexane, vortex mix briefly on a vortexer. 
x Add the 100 µl reconstitution mixture to an analysis vial and crimp. 
Figure 22: The original GC-MS extraction method. 
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Initial results appeared promising with 100% recovery of CrEL and the internal 
standard heneicosanoic acid, but subsequently the signal was lost. After a 
chemical reaction it is possible to calculate the remaining original substance, 
this result is calculated as a percentage and is termed percentage recovery.  
Values can either be less than 100% or greater, in the case of percentages 
exceeding 100% the results are inaccurate due to incorrect measurement or 
calculation.  Values below 100% are more desirable. 
 
The reason the signal was lost was not fully apparent, and the experiments 
were repeated using new columns but still proved unsuccessful. The loss of 
signal at this time may have been due to column saturation as a result of the 
chemical nature of the CrEL compound leading to a likely blockage (Figure 
23).  On reflection and after reading GC-MS troubleshooting guides a potential 
root cause could have been a reaction between the stationary phase in the 
column and the analyte (however the extraction method used had been 




Figure 23: Image showing the GC-MS spectrum produced after the injection of 
an extracted CrEL standard. Peaks such as these occurred when the column 






4.1. Method Validation 
 
After the development of an analytical method, the validation is the next key 
step to running the method routinely. Many validation guides are available for 
LC-MS/MS platforms. Reliable analytical data is of the foremost importance 
when treating patients.  
 
The Cremophor assay was developed and validated according to the methods 
published by J W Honour in 2011.51 This method covers all aspects of method 
development as recommended by the FDA and EMA guidelines on 
bioanalytical method validation.52, 53 
 
 The various steps include: 
 
4.1 Tuning and Selectivity of Ricinoleic acid 
4.2 Interference by ion suppression or enhancement 
4.3 Linearity 




4.8 Stability Studies 




The first step in LC-MS/MS method development is to determine the optimal 
parameters for ionisation of the parent compound. The instrument must be 
adjusted to establish the best resolution which relates to the width of the peak 
and the highest sensitivity which is the height of the peak.   
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It is advisable where possible to obtain quality chemical products or Certified 
reference materials (CRM).  
 
Waters recommend in their operators guide a set of starting parameters for 
each stage of tuning from parent ion through to daughter and qualifier ions. 
The following suggested conditions in tables 5 and 6 were used when 
Ricinoleic acid was tuned. During the tuning of the parent ion the parameters 
remain low or wide in range to allow the conditions for the ion to be 
optimised. The only gas applied to the compound at this point is the API gas 
nitrogen. Once the best conditions are applied to the parent ion and the 
resulting peak width and height has been seen the conditions are then 
changed to allow the fragmentation of the parent ion to occur (see figure 24). 
A collision gas in the form of argon is applied and the parent ion is subjected 
to a series of scans to help establish potential daughter ion peaks. Once the 
individual scans at 15 eV, 30eV and 45eV have been executed it is then possible 
to anticipate which potential fragments could be suitable daughter ions. Each 















 Sorts ions   Fragments ions  Sorts fragments 
 
 











Parameter Recommended value 
Voltages  
Capillary (kV) 3.00 
Cone (V) 50 
Extractor (V) 5 
RF Lens (V) 0.0 
Temperatures  
Source Temp () 120 
Desolvation Temp () 300 
Gas Flow  
Desolvation (L/hr) 700.0 
Cone (L/hr) 50 
Table 5: Recommended ES+ Source Page Parameter values Ȃ starting conditions 
to establish the parent ion. 
 
Parameter Recommended value 
Analyser  
LM Resolution 1 15.0 
HM Resolution 1 15.0 




LM Resolution 2 15.0 
HM Resolution 2 15.0 
Ion Energy 2 3.0 
Multiplier 550 
Table 6: Recommended Analyser Page Parameter values Ȃ starting conditions to 





For Ricinoleic acid, the product of alkaline hydrolysis of Cremophor EL, 
electrospray ionisation was used. In this method, as the compound elutes from 
the LC a gas in this case nitrogen was used to nebulize the eluent as it enters 
the mass spectrometer through a narrow capillary. A potential is applied to the 
capillary resulting in ionisation of the compound of interest. A heated 
desolvation gas is applied to the spray generated in order to help solvent 
evaporation. Ions can either form as pronated hydrogen adducts (M + 1) or as 
negative ions (M Ȃ 1) or as other adducts. In the case of Ricinoleic acid, ions 
were formed in the negative mode. 
 
Ionisation of Ricinoleic acid was achieved by infusing 1000 ug/L of the fatty 
acid in ethanol via post column (flow rate 20 µL/min) with 0.1% formic acid in 
DW/ ethanol (neat) (50:50) at a flow rate of 0.4 ml/min. The optimised 
capillary and cone voltages were 1kV and 32 V respectively. The source and 
desolvation temperatures were 1500C and 4000C respectively. The optimised 
molecular ion of Ricinoleic acid 297.3 and its principal daughter ion 





Figure 25: Parent molecular ion of Ricinoleic acid at 297.3. The image was 
obtained during the first stage of the tuning process when only the Cone and 
Desolvation gas (nitrogen) was applied. 
 
Figure 26: Quantifier daughter 182.9 ion of Ricinoleic acid. This image was 
obtained during the second stage of tuning when the parameters differ. The 
collision gas (argon) was applied allowing fragmentation to occur. The 




The fragmentation pattern for Ricinoleic acid at 15, 30 and 45 electron volts 
(eV) can be seen in Figure 27. Each scan at 15, 30 and 45 electron volts was 
performed independently of each other and compared. At 15 eV the scan 
indicates that more voltage is required to fully fragment the parent compound 
at 297.4. At 30 eV the scan indicates more complete fragmentation, the parent 
ion at 297.4 has reduced and the daughter fragmentation peak has appeared at 
183.2.   
 
 
Figure 27: Ricinoleic acid fragmentation patterns at 15, 30 and 45 eV. 
 
During method development, a suitable internal standard will be obtained and 
optimised using exactly the same procedure as the analyte of interest. 
Typically, an analogue form of the analyte that has three or more isotopic 
labels added to it are regarded as effective when possible. After tuning many 
internal standard compounds successfully, the internal standards were tested 
in an analytical batch. However, the internal standard showed poor 
reproducibility and lacked precision or accuracy. On some occasions, the 






Therefore, a suitable internal standard was not obtained that could survive the 
lipid extraction method or maintain precision.       
 
The final set of optimised ionisation parameters are shown in Table 7 
 
MS tune conditions 
 
Parameter Value/Condition 
Polarity  ES- 
Capillary (kV)  1.0 
Cone (V)  60 
Extractor (V)  3 
RF (V)  0 
Source Temperature (°C)  150 
Desolvation Temperature (°C)  400 
Cone Gas Flow (L/Hr)  800 
Desolvation Gas Flow (L/Hr)  1000 
Collision Gas Flow (mL/min)  0.25 
LM 1 Resolution  15 
HM 1 Resolution  15 
Ion Energy 1  0.5 
MS-MS Mode Entrance  -2 
MS-MS Mode Collision Energy  15 
MS-MS Mode Exit  1 
LM 2 Resolution 15 
HM 2 Resolution 15 
Ion Energy 2 3.0 
Multiplier(V) 663 
Syringe pump flow(µL/min) 20 
Collision cell pressure(mbar) 2.70e-3 
Collision gas flow(mL/min) 0.25 
Cone + Desolvation Gas Nitrogen 
Collision Gas Argon 
Table 7: MS tune parameters indicating the settings for each independently 
controlled quadrupole, the source condition and gas flow rates and 
temperatures. 
 





) was used to run aqueous standards of 1000 ug/L of Ricinoleic acid in order to 
determine the retention times.  
An isocratic elution remains at a constant uniform composition, whereas a 
gradient elution varies in the solvent strength typically low at the start leading 
to high near the end of the overall gradient.  
 
Option Setting 
Run time 5.00 
Load Ahead Enabled 
Loop Option Partial loop with needle overfill 
Loop Offline Disable 
Weak wash solvent 95/5   water:methanol  
Srong wash solvent IPA:ACN:MeOH:H20:FA 
Weak needle wash volume 1800 uL 
Strong needle wash volume 600 uL 
Column temperature 50.0 C 
Sample temperature off 














1  0.400 3.0 97.0  
2 5.00 0.400 3.0 97.0 6 
Table 9: LC Isocratic Settings 
 




Figure 28: Chromatogram of aqueous standard of Ricinoleic acid eluting at 2.80 
minutes. 
 
4.3. Ion Suppression and Enhancement 
 
Ion suppression and enhancement is a potential problem in the development 
of LC-MS/MS methods relating to matrix effects. It is related to the efficiency 
of the ionisation from likely phospholidids found in human samples.  In order 
to exclude significant ion suppression or enhancement from matrix effect 1000 
ug/ml of aqueous Ricinoleic acid was infused post column whilst an extracted 
FFP without Ricinoleic acid was injected into the LC. There was evidence of 
about 40% ion suppression at about 0.6 minutes but before the eluting time of 





Figure 29: Chromatogram showing about 40% ion suppression at 0.6 minutes. 
 
As shown in Figure 30 and subsequent experiments, there was no evidence of 
any significant effect on linearity, precision and accuracy. 
 






A standard curve of Ricinoleic acid was prepared in FFP with concentrations 
ranging from 0.313 µL/ ml to 10 µL/ ml. Previous pharmacokinetic studies of 
the disposition of Cremophor EL after infusion of Paclitaxel an anticancer drug 
shows that the concentration of Cremophor EL rarely peaks beyond 10 ul/ ml. 3 
A sample of a standard curve of Cremophor EL after extraction from FFP is 
shown in Figure 30. Generally, the linearity was greater than r2 = 0.98.  
 
4.5. Accuracy and Recovery 
 
As Cremophor is not a naturally occurring substance in human plasma, 
relative recovery was determined by spiking blank FFP and determining 
percentage recovery at two concentrations of Ricinoleic acid at low 0.313 µL/ 
ml and high 5 µL/ ml (n = 10). Results (Table 10) showing excellent recovery. 
 
Spiked (µL/ ml) Mean (µL/ ml) 
(n = 10) 
% Recovery 
(n = 10) 
Standard 
Deviation 
0.313 0.277 88.5% 0.04 
5 5.015 100% 0 






Intra assay precision of the method was determined by running 9 replicates of 
low (0.313 µL/ ml), and high (5 µL/ ml) samples. Co-efficient of variation (CV) 
was calculated. The day to day precision was determined over 3 days at the 
same concentrations. Results are presented in Table 11. The assay showed 
excellent precision over 3 consecutive days at both low and high 











0.313 10 19 22 17 
5 8 9 13 10 
Table 11: Intra-assay and day to day variation at different concentrations of 
Cremophor. 
 
4.7. Sensitivity (Lower Limit of Quantification, LLOQ) 
 
Previous pharmacokinetic studies of the disposition of Cremophor EL after 
infusion of Paclitaxel an anticancer used a standard curve with concentrations 
of the drug ranging between 0.5 to 10 ul/ ml.3 In this study we have extended 
this range from 0.313 to 10 ul/ ml. The intra assay and day to day precision at 
0.313 ul/ ml was about 10% (precision table) whilst the signal to noise ratio was 
constantly above 10 (Table 12).  This fits into the acceptance criteria for LLOQ 
which is the lowest measurable amount at precision of < 20% and signal to 




Sample 0.313 ul/ ml  
Recovery 
S/N ratio at 0.313 ul/ 
ml 
1 0.29 62 
2 0.22 90 
3 0.26 48 
4 0.25 82 
5 0.22 77 
6 0.29 65 
7 0.26 60 
8 0.28 76 
9 0.26 58 
Mean 0.259  
CV % 10%  








Carryover is the appearance of the analyte in a run when a blank containing 
no analyte is injected. Carryover was assessed by injecting a high 
concentration at 5 µL/ml over 10 consecutive runs and comparing response to 




The chromatograms of the extracted FFP blanks were examined for any 




Figure 31: Alternate chromatographic runs of 5 ul/ml of cremophor alternating 
with extracted FFP blank showing no evidence of carry over of sample into the 
blanks. Retention time 0.7 min 
 
4.9. Stability Studies 
 
Stability studies are typically conducted in a pharmaceutical setting to ensure 
that developed medicinal products retain their quality, safety and efficacy 
throughout a planned shelf life. In the analytical chemistry setting the stability 
studies serve to establish the most suitable storage conditions for the product, 
drug or chemical. Usually the studies are planned to replicate the conditions 
the product or samples would encounter. A suitable range of temperatures is 
also included in a study to allow for all eventualities. Transportation and pre-




Chemically, it is also important to include the following factors when 
conducting experiments with active ingredients; interaction between active 
ingredients and excipients, processes during manufacture, the type of dosage 
form, the container system used and how the product was protected from 
heat, light and moisture during transportation. Fluctuations in temperature 
could result in freezing, thawing or shearing.  
 
Stability studies were undertaken to replicate storage and transportation 
conditions prior to analysis of Cremophor at 40C and at -200C 
 
Aliquots (10) at concentrations of 1.25 µL/ml and 5 µL/ml each, were stored at 
+4°C and -200C for 1 week and analysed. Results were compared to aliquots 





     (µL/ml) 






1.25 9.0 10.0 9.5 
5 7.5 9.5 8.5 
n 10 10  
Table 13: Sample Stability at 40°C for 1 week 
   
Frozen Samples 
 
Ten aliquots of spiked plasma samples, 0.625 µL/ml and 5 µL/ml were stored 
at -20°C for 1 week to again replicate storage conditions if the samples were 
frozen transported before being analysed. Acceptance criteria was a CV of 





     (µL/ml) 




1 Month Mean  
(CV%) 
0.625 9.5 9.5 10.7 9.9 
5 8.0 7.5 6.9 7.5 
n 10 10 10  
Table 14: Sample Stability at -20°C for 1 week 
 
Stability of Stock Solutions 
   
Stock solutions and standards were protected from direct sunlight and kept in 
a locked solvent store.  
 
Stability of Processed Samples 
   
To eliminate the possibility of detrimental effects of delays in analysis due to 
instrument problems, sample extracts were divided into two sets. The first set 
was analysed immediately or within the normal time delay from extraction to 
analysis. The second set was injected after 24 hours storage at 40C. The UPLC-
MS/MS equipment has the added advantage of a refrigerated sample store. 
This capability prevents sample degradation during analysis and batch runs, 
ensuring that all the samples remain the same temperature throughout the 
assay.    
 
The results of the stability studies for Cremophor EL in plasma proved 
successful throughout all experiments tested at both 4 and -20. ǯ
for all the tested parameters indicates that if patient samples were delayed in 







CrEL is challenging and difficult compound to quantify in plasma or serum, 
especially when talking in terms of precision and reproducibility. This 
challenge was overcome by using UPLC-MS-MS as the analytical tool on the 
basis that it should give much improved specificity and sensitivity, speed of 
analysis and cost efficiency.  
We reached a stage where we developed a method which could be applied to 
samples from this study but believed that improvements could still be made 
over time and we have taken advantage of unexpected delays in the study start 
to use this extra time to continue to develop the methodology.  
There are very few reference methods for the analysis of Cremophor and all 
report problems with linearity and precision over the expected therapeutic 
range / concentration detection of 0.5-10.0µm/L.  
A modification of the Coomassie Blue method (Sparreboom et al 1998)39 using 
dual wavelength spectrophotometry improved precision and reproducibility 
though the application of a complex software package, transforming the 
calibration graph.  With this method samples have to be analysed in duplicate 
and each singleton itself analysed twice.  
There are also published HPLC (High Performance Liquid Chromatography) 
methods with UV (Ultraviolet) detection (Ghassempour et al 2003)2 which 
require labour intensive sample preparation with long run times. A method 
using pyrolysis and Gas Chromatography with Mass Spectrometry has also 
been published but the instrumentation for the former is not readily available. 
During the initial method development process, a Gas Chromatography Mass 
Spectrometry (GC-MS) method with lipid specific columns was tested. This 
involved chloroform-methanol extraction, hydrolysis using sodium hydroxide 
and methylation using boron trifluoride.  
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Initial results were promising but subsequently the signal was lost. The reason 
for this was not apparent, and the experiments were repeated using new 
columns but still proved unsuccessful. The loss of signal at this time may have 
been due to the cremophor compound saturating the column blocking it.  
To overcome the encountered problems with GC-MS an Ultra Performance 
Liquid Chromatography (UPLC) linked to Tandem Mass Spectrometry was 
investigated. LC-MS/MS is a brilliant analytical tool offering rapid separation 
and identification of compounds. A method was initially developed using a 
modified Liquid Chromatography Mass Spectrometry (LC-MS) method using 
selective ion monitoring (SIM), but it suffered from interference from solvents 
and buffers. The precision was poor and unacceptable for validation. A 
subsequent method was developed to a stage where it was sufficiently reliable, 
where it was then validated to show it was fit for purpose. The current method 







5.1. Summary and Conclusion  
 
A UPLC tandem mass spectrometry method has been developed and validated 
for measuring CrEL. This method showed very good linearity, accuracy, 
recovery, precision, sensitivity, with little evidence of carry-over. This method 
will be used in a to analyse patient study samples examining the use of 
Dexanabinol prepared in CrEL as a chemotherapeutic agent. The current SOP 
used in the laboratory is in appendix 6.2.  
 
5.2. Future work 
 
Additional work could include finding a suitable internal standard that could 
survive the extraction process. Many examples currently exist in some of the 
reviewed literature papers. Examples of these fatty acid compounds are in 




Margaric acid 270.45 






Table 15: Additional internal standard options 
 
More recently a potential way to increase the productivity of the CrEl 
extraction was bought, in the form of an oversized mechanical mixer produced 
by Lab-tek International (Figure 32) (Christchurch, New Zealand). The mixer 
was purchased because of its time saving nature and capability to 
accommodate large batch assays. Glass tubes remain in their original rack and 




When the arm is pressed down the foam compresses around the screw top 
tubes holding them in place and a screw knob is then tightened to stop the 
arm rising. The shaker has a speed dial giving a range of 300-2800 rpm and 
two setting of continuous or timed mixing. The old system for mechanical 
shaking involved the transfer of each glass tube and pressing them in to a 
polycarbonate rack fixed on top of the shaker (Figure 32). This system has a 
maximum capacity of 36 spaces and when undertaking large batches of over 
100 tubes can be tiresome. In comparison, the large mechanical shaker can 
accommodate a rack of 50 -80 samples depending on the type of rack used. 
Samples are mixing in around two minutes using the Lab-tek system meaning 
extractions could be accomplished in less time. In particular, this assay has 
three separate steps where mixing is required and the overall time saving 
could be close to one hour of saved analyst time.  
 
  
Figure 32: Comparison images of a Lab-tek international vortexer and a IKA 
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6.1. Appendix 1: GC-MS parameters  
 
 
                      INSTRUMENT CONTROL PARAMETERS:    agilent gcms toxics 
                                  ----------------------------------------------------- 
 
   C:\MSDCHEM\1\METHODS\cremaphor slow.M 





Sample Inlet      :  GC 
Injection Source  :  GC ALS 










   Initial temp:  80 'C (On)               Maximum temp:  340 'C 
   Initial time:  0.00 min                 Equilibration time:  0.50 min 
   Ramps: 
      #  Rate  Final temp  Final time 
      1 10.00      320        5.00 
      2   0.0(Off) 
   Post temp:  0 'C 
   Post time:  0.00 min 
   Run time:  29.00 min 
 
 
FRONT INLET (SPLIT/SPLITLESS)           BACK INLET (UNKNOWN) 
   Mode:  Pulsed Splitless 
   Initial temp:  250 'C (On) 
   Pressure:  9.59 psi (On) 
   Pulse pressure:  23.0 psi 
   Pulse time:  2.00 min 
   Purge flow:  48.8 mL/min 
   Purge time:  0.25 min 
 97 
 
   Total flow:  53.8 mL/min 
   Gas saver:  On 
   Saver flow:  15.0 mL/min 
   Saver time:  2.00 min 
   Gas type:  Helium 
 
 
COLUMN 1                                COLUMN 2 
   Capillary Column                        (not installed) 
   Model Number:  J&W 122-4712 
   DB-17ms 
   Max temperature:  320 'C 
   Nominal length:  15.0 m 
   Nominal diameter:  250.00 um 
   Nominal film thickness:  0.25 um 
   Mode:  constant pressure 
   Pressure:  9.59 psi 
   Nominal initial flow:  2.0 mL/min 
   Average velocity:  75 cm/sec 
   Inlet:  Front Inlet 
   Outlet:  MSD 
   Outlet pressure:  vacuum 
 
 
FRONT DETECTOR (NO DET)                 BACK DETECTOR (NO DET) 
 
 
SIGNAL 1                                SIGNAL 2 
   Data rate:  20 Hz                       Data rate:  20 Hz 
   Type:  test plot                        Type:  test plot 
   Save Data:  Off                         Save Data:  Off 
   Zero:  0.0 (Off)                        Zero:  0.0 (Off) 
   Range:  0                               Range:  0 
   Fast Peaks:  Off                        Fast Peaks:  Off 
   Attenuation:  0                         Attenuation:  0 
 
 
COLUMN COMP 1                           COLUMN COMP 2 
   (No Detectors Installed)                (No Detectors Installed) 
 
 
THERMAL AUX 2 
   Use:  MSD Transfer Line Heater 
   Description: 
   Initial temp:  280 'C (On) 
   Initial time:  0.00 min 
      #  Rate  Final temp  Final time 
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      1   0.0(Off) 
 
 
                                        POST RUN 









                               GC Injector 
 
 
     Front Injector: 
        Sample Washes                 0 
        Sample Pumps                  3 
        Injection Volume           2.00 microliters 
        Syringe Size               10.0 microliters 
        PreInj Solvent A Washes       4 
        PreInj Solvent B Washes       4 
        PostInj Solvent A Washes      3 
        PostInj Solvent B Washes      3 
        Viscosity Delay               3 seconds 
        Plunger Speed              Fast 
        PreInjection Dwell         0.00 minutes 
        PostInjection Dwell        0.00 minutes 
 
 
     Back Injector: 
No parameters specified 
 
 Column 1 Inventory Number : js002 
 Column 2 Inventory Number :   
 






Tune File                : atune.u 








Solvent Delay            : 0.90 min 
 
EM Absolute              : False 
EM Offset                : 0 




Low Mass                 : 25.0 
High Mass                : 550.0 
Threshold                : 150 




MS Source                : 230 C   maximum 250 C 
MS Quad                  : 150 C   maximum 200 C 
 
 
                             END OF MS ACQUISITION PARAMETERS 
 
 
                              TUNE PARAMETERS for SN: us52420874 
                        ----------------------------- 
 
 Trace Ion Detection is OFF. 
 
 EMISSION    :      34.610 
 ENERGY      :      69.922 
 REPELLER    :      25.264 
 IONFOCUS    :      90.157 
 ENTRANCE_LE :      16.000 
 EMVOLTS     :    1564.706 
 AMUGAIN     :    1680.000 
 AMUOFFSET   :     125.500 
 FILAMENT    :       2.000 
 DCPOLARITY  :       0.000 
 ENTLENSOFFS :      20.329 
 MASSGAIN    :    -768.000    
 MASSOFFSET  :     -34.000    
 
                           END OF TUNE PARAMETERS 






                                          END OF INSTRUMENT CONTROL PARAMETERS 






6.2. Appendix 2: Standard operation procedure (SOP) 
 













To determine and quantify the presence of Cremophor in EDTA human 
plasma samples. Cremophor is a nonionic solubiliser and emulsifier which is 
commonly used in the pharmaceutical industry as an additive or excipient. 
Modern drugs are rarely administered in their pure chemical state and often 
use an excipient combined with the active compound to enable the transport 
of active drug to its target site. Examples of drugs using cremophor as an 
excipient include Dexanabinol, Benzocaine and Hexedetine.There is evidence 
that Cremophor may exhibit human toxicity and it is therefore necessary to 
monitor its levels in drug trials. 
 
 
Principle of method 
Cremophor (Polyoxyethyleneglycerol triricoleate 35) undergoes alkaline 
hydroxylation to form ricinoleic acid which is measured by Liquid 
chromatography tandem mass spectrometry (LC-MS/MS). This is performed 
by a Waters Quattro Premier XE system. Analyte separation is by an Acquity 
UPLC HSS T3 1.8µm column followed by gradient elution with 0.1% formic 
acid in deionised water and neat ethanol delivered at a flow rate of 
0.4mL/min. Ionisation is achieved by the transfer of a 1kV capillary voltage to 
the molecules and protonation from the desolvation gas (nitrogen) delivered 
at a flow rate of 800L/hr to form negative molecular ions (M-HǇȌ in an 
ǲǇ ǳǤ are fragmented to product ions following 
the reaction with the collision gas (argon) and monitored by a detector. 
System operation and data acquisition are controlled using Waters MassLynx 
V4.1 software. Data processing is controlled by TargetLynx V4.1 software. 
 
Specimen type required 
EDTA plasma. 
 
Reagents and equipment 
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When handling reagents that are identified as a risk, staff MUST take 
precautionary measures and familiarise themselves with COSHH data and 
decontamination procedures before continuing. 
 
LCMSMS System 
Acquity UPLC (serial number DO9 UPA 880M, Waters, UK) 
HSS T3 1.8µm column (part no: 186003539, Waters, UK) 
Waters Quattro Premier XE LC-MS/MS system (serial number VAB 1255, 
Waters, UK) 
IKA Vibrax VXR Basic (mechanical shaker)  
Beckman Spinchron ?DLX Centrifuge 
Techne Ȃ Driblock and Sample Concentrator  
 
Standards   Supplier Hazard 
Cremophor EL  Sigma  NOT KNOWN Ȃ HANDLE WITH 
CARE 





Acetonitrile   Fisher  IRRITANT, WEAR 
GLOVES/GOGGLES  
Ethanol   Fisher  TOXIC, WEAR GLOVES/GOGGLES 
Formic acid, 98/100% VWR  IRRITANT, WEAR 
GLOVES/GOGGLES 
Isopropanol   Fisher  FLAMMABLE, WEAR 
GLOVES/GOGGLES 
Methanol   Fisher  FLAMMABLE, WEAR 
GLOVES/GOGGLES 
Methanol (LCMS grade) Fisher  FLAMMABLE, WEAR 
GLOVES/GOGGLES 
Millipore deionised water  
 
Extraction solvents and chemicals 
 
Chloroform   Fisher  FLAMMABLE, WEAR 
GLOVES/GOGGLES  
Diethyl ether   Fisher  FLAMMABLE, HARMFUL 
Ethanol   Fisher  TOXIC, WEAR GLOVES/GOGGLES  
Ethyl acetate   Fisher  FLAMMABLE, WEAR 
GLOVES/GOGGLES 
Hexane   Fisher  FLAMMABLE, WEAR 
GLOVES/GOGGLES 







Sodium chloride  Fisher  IRRITANT, WEAR 
GLOVES/GOGGLES 
Sodium hydroxide   Sigma  CORROSIVE, WEAR 
GLOVES/GOGGLES 
Sodium sulphate  Sigma  IRRITANT, WEAR 
GLOVES/GOGGLES   
Butylated hydroxytoluene Sigma  HARMFUL, IRRITANT, WEAR 
GLOVES/GOGGLES 
Molecular sieves (AW-300) Sigma  IRRITANT, WEAR GLOVES/GOGGLES 
 
(Sodium Sulphate is hygroscopic in nature and must be kept away from 







Chromacol - glass analysis vials and caps 
LabCo -10mL/5mL glass tubes and screw tops 
Fisher scientific - Pasteur pipettes, glass unplugged, (150mm)  





Mobile Phase A2: 0.1% formic acid in deionised water 
Add 1ml formic acid to 999ml millipore DW. Stable for 1 month at room 
temperature. 
 
Mobile Phase B2: 
Ethanol. Ready to use, kept in lockable solvent bin. Record useage.in ethanol 
record book. 
 
Strong needle wash 
Decant 250mL methanol, 250mL acetonitrile, 250mL isopropanol, 250mL DW 
and 2mL formic acid 98/100% into a container and mix. Stable for 6 months at 
room temperature. 
 
Weak needle wash 












Chloroform: methanol (2:1 v/v) with 50mg/L Butylated hydroxytoluene (BHT). 
Accurately weigh out 50mg of BHT, add 667mL of chloroform to 333mL of 
methanol. Add BHT to solvent mixture and mix thoroughly. Stable for 6 
months at room temperature. 
 
2M Sodium hydroxide in methanol 
 
Accurately weigh out 40g of sodium hydroxide pellets and add to 500mL 
LCMS grade methanol and mix. The prepared solution is then heated in an 
ultrasonic bath set at 50°C until all the sodium hydroxide pellets have 
dissolved. Stable for 3 months at room temperature. 
 
1M Sodium chloride in deionised water 
  
Accurately weigh out 58.44g of sodium chloride and add 1 litre of deionised 






Preparation of stock standard (20µL/mL)  
Separately add 2ml stock Cremophor EL add 98ml FFP. Mix thoroughly using 
a magnetic stirrer. Decant as 1.5ml aliquots. Store at Ȃ20oC. 
 
Preparation of 5µL/mL cremophor internal quality control 
Add 1mL 20µL/mL Cremophor EL stock standard to 3mL FFP. Mix thoroughly 
using a magnetic stirrer. Store at Ȃ20oC in LEC lockable Forensic toxicology 
freezer as 200µL aliquots. 
 
Preparation of 0.6µL/mL cremophor quality control 
Add 500µL 5µL/mL cremophor internal quality control to 3.5mL FFP. Mix 
thoroughly using a magnetic stirrer. Store at Ȃ20oC in LEC lockable Forensic 
toxicology freezer as 200µL aliquots. 
 
 
Working Standard curve 
Double dilute the 20µL/mL cremophor stock standard  in FFP to produce a 





Prepare a worksheet 8.14 Cremophor worksheet 
     
Procedure 
Preparation of sodium sulphate extraction columns 
Before running the assay ensure that a sufficient stock of Sodium sulphate 
columns are made.Sodium sulphate columns are constructed from glass 
Pasteur pipettes, cotton wool and sodium sulphate crystals. The cotton wool 
acts as a plug to prevent the crystals from leaving the pipette.  
 
Carefully push a pinch of cotton wool inside the glass shaft to the neck of the 
pipette. Ensure the cotton wool plug is gently eased down to the neck of the 
pipette using a thin spatula. Do not compact the cotton wool plug as this can 
create problems during the extraction process.  
To each glass Pasteur add six small spatula scoops of sodium sulphate crystals. 
Store the columns in an airtight container away from moisture. The sodium 
sulphate acts as a desiccant. 
 
Chloroform: methanol Lipid Extraction  
Perform this procedure under forced ventilation 
Add 200µL sample/qc/standard to a 10mL Labco tube. Add 5mL of chloroform: 
methanol:BHT (2:1,v/v) mixture. Add 1mL of 1M sodium chloride and vibramix 
for 5 minutes at 1000 rpm. Next, centrifuge samples for 10 minutes at 3000rpm. 
The samples should be clearly separated with two defined layers.  
 
Carefully collect the lower chloroform phase using a glass Pasteur pipette 
ensuring the layers remain separated and transfer this to another 5mL labco 
tube.  
 
For each sample wash a sodium sulphate column with 1.5mL diethyl ether 
using a dispenser bottle. Allow the ether to drain by gravity through the 
column into a waste beaker.  
 
Apply sample to washed column and collect filtrate into a 10mL labco tube. 
 
Add 1.5mL diethyl ether to the column and collect the filtrate into the 10mL 
labco tube..   
ǲ-ǳ
flow regulator at about 5 bar. This should take approximately 50 minutes.  
 
 
Alkaline hydrolysis of Cremophor to Ricinoleic acid 
1.Add 2mL of 2M sodium hydroxide in methanol to the dried extract and 
vibramix for 5 minute at 1600rpm. Heat at 80°C for 60 minutes in the heating 




2.Add 2.5mL of Millipore water and 2.5mL of hexane. Vortex mix the solution 
and transfer the supernatant to an LP4 glass culture tube using a glass Pasteur 
pipette.   
 
 ?Ǥǲ-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regulator at  2- 4 bar. 
 
Reconstitution 
Add 500µL of ethanol to each dry eluate, vortex mix, transfer 300µL to 




At the desktop, select MassLynx V1 icon. The sample loader will initialise. 
Upload assay method 
Select Instrument tab followed by the inlet method icon. 
Select file, open and select method file ricinoleic acid ethanol. wvhp. 
 
Pre-run 
Check waste containers situated in the spill tray under the instrument and 
ensure all solutions are in sufficient quantity to complete the assay. 
Load the inlet method ricinoleic acid ethanol6.wvhp as shown in Table 1 and 
click on the load icon. Allow to run for 15 minutes. 
 
 
Table 1 isocratic elution program for cremophor method 
Time (min) Flow (ml/min) A2 (%) B2 (%) 
initial 0.4 3.0 97.0 
5.00 0.4 3.0 97.0 
 
Flow is confirmed by the green light.  
Select the Launch acquity UPLC console icon (situated 2nd icon RHS) and 
ensure delta<100.If not consult a senior member of staff. 
 
Switch on inlet gas and collision gas 
In MassLynx, select instrument tab and select MS Tune icon 
Open Ricinoleic acid_MSMS file 
Click on Gas and select Inject 
Switch inlet gas ON by toggling the API gas icon on top toolbar 
Switch collision gas ON by toggling the COL gas icon on the top toolbar 




Open the door to the sample manager module of the LC-MS/MS system and 
remove well plate 1 by pressing on the grey tab of the well plate tray holder 
and withdraw holder. Remove the well plate and load samples according to 
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the worklist. Reset the well plate (nb cut-off corner orientated towards top 
RHS) and push holder back into position until assembly clicks into place. 
Close the sample manager door. 
 
Program worklist 
In MassLynx, select file, open and select a previous worklist eg 
Cremophor20120416 (format is test name yyyy/mm/dd) and edit as follows: 
File name 
Edit data file name in the format Test-Year-Month-Day-File number eg 
Cremophor2012041601.To autoincrement, highlight first entry, press shift and 
highlight your last entry, right click and Fill series 
Sample ID 
Enter blk, std, qc or sample lab number 
File text 
Enter patient surname and sample type 
Tune file 
Ensure mstune file = Ricinoleic acid MSMS 
Method file 
Ensure ms file= Ricinoleic acid acetonitrile 
Inlet method file 
Ensure inlet file= ricinoleic acid ethanol  
nb to change these files, double left click field and select desired option 
Bottle 




Enter std, qc, analyte 
Conc A 
Enter the standard concentrations in the appropriate fields 
 
 
Save the worklist, select file, save as and save in the Sample DB folder. 






Ensure that the source and desolvation temperatures have reached their set 
points. 
Highlight the worklist by holding down the left mouse button and press the f 
icon on the top toolbar. In start sample list run window ensure the number of 
samples to be analysed corresponds with the worklist and all tabs are ticked 
except pre- and post-run options and select OK. At Create TargetLynx dataset 





To calculate results 
In MassLynx, select QuanLynx tab, highlight the worklist and select Process 
samples.  
 
To view chromatograms/results 
In QuanLynx, select view results. Check that the calibration curve is linear 
and the fit is good, ie correlation coefficient R2>0.98.  
For all samples, QC and standards check the following: 
1, The standard has integrated correctly and the peak area is acceptable. 
2, The retention time for the analyte quantifier ion peak is correct and the 
peak has integrated correctly. 
3, There is a corresponding qualifier peak with the same retention time as the 
quantifier ion peak. 
If in doubt, refer to a senior member of staff. 
Results are reported as µL/mL. 
 
Compound elution times should be as follows: 
Compound  Approximate retention time (min)   
 





To view ions 
Select MS method 
 
MRM transitions are as follows: 
Compound     Parent ions (m/z) 
 Daughter ions (m/z) 
Ricinoleic acid     297.3   182.9 
   
 
QC Interpretation 
Enter data for internal quality control into QCPLUS. Acceptance criteria is 
stated as being within 2SD of the assigned mean. If QC is outside these limits 
inform a senior member of staff. 
 
Reporting results 
Lower level of quantitation 0.07µL/mL. Report levels as <0.07µL/mL if less 
than lower level of quantitation. 
Upper level of quantiation 10µL/mL. Re-analyse levels >10µL/mL in the next 
assay as a 1:2 dilution in FFP. 
 






The method is traceable to the following standards 
Ricinoleic acid , Cat No. R7257 purity >99%   Sigma-Aldrich 




Uncertainty is defined in Q3.9 Traceability and Uncertainty and values are 
stored in Q3.9a Uncertainty of measurement values.xlsx. 
Where EQA and IQC is available the uncertainty is calculated as 1.96*SD + 
Absolute Bias.  
For binary results the uncertainty of Positive or negative results as a 
percentage is reported for the process utilising the positive predictive value or 
the negative predictive value.  
If none of these are possible then it is calculated from the constituent 
uncertainties of the process 
. 
There are currently no External Quality Assurance (EQA) schemes for 
Cremophor to compare against. 
 
Risk assessment 
Low overall risk if this procedure is performed using good laboratory practice 





Toxics validation: FTV7- The Development and Validation of a Liquid 
Chromatography Tandem Mass Spectrometry Method for Cremophor EL in 
Human Plasma. 
 
COSHH assessments and MSDS documents are stored in QPulse. 
 
 
